Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated:  3/28/2016
Windy Hill Village
mi
from
Philipsburg, PA
Cognitive Intervention For Delirium in Dementia
Reserve For Delirium Superimposed On Dementia (DSD)
Status: Enrolling
Updated: 3/28/2016
Windy Hill Village
mi
from
Philipsburg, PA
Click here to add this to my saved trials
Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease
Immediate Effects of Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease
Status: Enrolling
Updated:  3/28/2016
The Ohio State University Physical Therapy Division
mi
from
Columbus, OH
Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease
Immediate Effects of Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease
Status: Enrolling
Updated: 3/28/2016
The Ohio State University Physical Therapy Division
mi
from
Columbus, OH
Click here to add this to my saved trials
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
Status: Enrolling
Updated:  3/28/2016
Oakland University
mi
from
Rochester, MI
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
Status: Enrolling
Updated: 3/28/2016
Oakland University
mi
from
Rochester, MI
Click here to add this to my saved trials
Study of Milk Allergy and Tolerance in Children
Dietary Intervention in Milk Allergy and Tolerance Development
Status: Enrolling
Updated:  3/29/2016
Mount Sinai School of Medicine
mi
from
New York, NY
Study of Milk Allergy and Tolerance in Children
Dietary Intervention in Milk Allergy and Tolerance Development
Status: Enrolling
Updated: 3/29/2016
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Characterization and Treatment of Chemotherapy Neuropathy
Characterization of and Treatment for Chemotherapy-Induced Neuropathy
Status: Enrolling
Updated:  3/29/2016
University of California
mi
from
San Francisco, CA
Characterization and Treatment of Chemotherapy Neuropathy
Characterization of and Treatment for Chemotherapy-Induced Neuropathy
Status: Enrolling
Updated: 3/29/2016
University of California
mi
from
San Francisco, CA
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Cullman, AL
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Tuscon, AZ
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Newport Beach, CA
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Ft. Collins, CO
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Ft. Collins, CO
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Dover, DE
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Dover, DE
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Miami, FL
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Sunrise, FL
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Sunrise, FL
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Atlanta, GA
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Foxboro, MA
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Foxboro, MA
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Golden Valley, MN
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Stratford, NJ
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Stratford, NJ
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Patchogue, NY
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Patchogue, NY
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Hickory, NC
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Dayton, OH
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Greensburg, PA
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Greensburg, PA
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Spartanburg, SC
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Knoxville, TN
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated:  3/29/2016
Clinical Research Facility
mi
from
Mansfield, TX
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
Status: Enrolling
Updated: 3/29/2016
Clinical Research Facility
mi
from
Mansfield, TX
Click here to add this to my saved trials
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Pilot Trial of Lithium in Progressive Multiple Sclerosis
Status: Enrolling
Updated:  3/30/2016
Kirklin Clinic
mi
from
Birmingham, AL
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Pilot Trial of Lithium in Progressive Multiple Sclerosis
Status: Enrolling
Updated: 3/30/2016
Kirklin Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Pilot Trial of Lithium in Progressive Multiple Sclerosis
Status: Enrolling
Updated:  3/30/2016
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Pilot Trial of Lithium in Progressive Multiple Sclerosis
Status: Enrolling
Updated: 3/30/2016
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus TPI 287 in Adults With Recurrent Glioblastoma
Status: Enrolling
Updated:  3/30/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus TPI 287 in Adults With Recurrent Glioblastoma
Status: Enrolling
Updated: 3/30/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Status: Enrolling
Updated:  3/30/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Status: Enrolling
Updated: 3/30/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Status: Enrolling
Updated:  3/30/2016
University of Montreal
mi
from
Montreal,
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Status: Enrolling
Updated: 3/30/2016
University of Montreal
mi
from
Montreal,
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Albany Advanced Imaging
mi
from
Albany, NY
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Albany Advanced Imaging
mi
from
Albany, NY
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Fallon Wellness Pharmacy
mi
from
Latham, NY
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Fallon Wellness Pharmacy
mi
from
Latham, NY
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Northeast Eye Center
mi
from
Latham, NY
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Northeast Eye Center
mi
from
Latham, NY
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
The MS Center of Northeastern New York
mi
from
Latham, NY
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
The MS Center of Northeastern New York
mi
from
Latham, NY
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Cleveland Clinic
mi
from
Cleveland, OH
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Retina Vitreous Center
mi
from
Edmond, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Retina Vitreous Center
mi
from
Edmond, OK
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Lynn Health Science Institute
mi
from
Oklahoma City, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Radiology Associates (X-ray facility only)
mi
from
Oklahoma City, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Radiology Associates (X-ray facility only)
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Pfizer Investigational Site
mi
from
Cleveland, OH
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Pfizer Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Pfizer Investigational Site
mi
from
Edmond, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Pfizer Investigational Site
mi
from
Edmond, OK
Click here to add this to my saved trials
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/30/2016
Pfizer Investigational Site
mi
from
Oklahoma City, OK
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/30/2016
Pfizer Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Botulinum Toxin and Recovery of Hand Function After Stroke
Botulinum Toxin Type A Therapy as a Plasticity Inducing Agent for Recovery of Hand Function After Stroke
Status: Enrolling
Updated:  3/31/2016
New York University School of Medicine
mi
from
New York, NY
Study of Botulinum Toxin and Recovery of Hand Function After Stroke
Botulinum Toxin Type A Therapy as a Plasticity Inducing Agent for Recovery of Hand Function After Stroke
Status: Enrolling
Updated: 3/31/2016
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion
Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion
Status: Enrolling
Updated:  3/31/2016
Michigan NeuroSport Concussion Program
mi
from
Ann Arbor, MI
Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion
Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion
Status: Enrolling
Updated: 3/31/2016
Michigan NeuroSport Concussion Program
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Washington,
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
New York, NY
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials